Activation of B-cell receptor (BCR) and NFκB promotes cell survival in the tumor microenvironment of CLL, and thus constitutes an important mechanism of drug resistance [27]. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.